Directory Profile

Samuel M. Poloyac, PharmD, PhD

Office: 212 Salk Pavilion, 335 Sutherland drive, Pittsburgh PA 15261

Phone: 412-624-4595

Fax: 412-624-1850

Email: poloyac@pitt.edu

pubmedLinkedIn

Samuel M. Poloyac, PharmD, PhD, FCCM is a Professor of Pharmaceutical Sciences and the Associate Dean for Graduate and Postdoctoral Programs at the University of Pittsburgh School of Pharmacy. Dr. Poloyac also serves as the Director of the Center for Clinical Pharmaceutical Sciences and the Director of the Small Molecule Biomarker Core Laboratory at the University of Pittsburgh. Dr. Poloyac is also an Associate Director at the Safar Center for Resuscitation Research. Dr. Poloyac graduated from the University of Pittsburgh with a BS in Pharmacy (1993), and then completed his PharmD (1995) and PhD (1999) degrees at the University of Kentucky.

Upon returning to the University of Pittsburgh as a faculty member (1999), Dr. Poloyac has focused on determining the role of drug metabolizing, cytochrome P450, enzymes on fatty acid bioactivation and drug disposition in the pathogenesis of disease in critically ill patients. Research in his laboratory utilizes relevant models of disease and translates these findings to critically ill patients. The NIH and the American Heart Association have supported his research, leading to over 100 peer-reviewed publications.

Dr. Poloyac has served as a reviewer for the National Institutes of Health and for numerous scientific journals. Dr. Poloyac is a Fellow of the Society of Critical Care Medicine and is a 2015-16 Fellow of the AACP Academic Leadership Fellow Program. Dr. Poloyac is committed to the advancement of pharmacy and pharmaceutical sciences both through research and through the training of the next generation of pharmacists and pharmaceutical scientists.


Critical care pharmacology and the role of cytochrome P450 enzymes in the pathogenesis of critical care illness.

RESEARCH PUBLICATIONS 2016 - 2020
1. Heinsberg LW, Alexander SA, Crago EA, Minster RL, Poloyac SM, Weeks DE, Conley YP. Genetic Variability in the Iron Homeostasis Pathway and Patient Outcomes After Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care. 2020; April 3 [Epub ahead of print]. PMID: 32246437.

2. Ma W, Sun J, Xu J, Luo Z, Diao D, Zhang Z, Oberly PJ, Minnigh MB, Xie W, Poloyac SM, Huang Y, Li S. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier. Theranostics. 2020; 10(6): 2463-2476. PMID: 32194813.

3. Jauhari A, Baranov SV, Suofu Y, Kim J, Singh T, Yablonska S, Li F, Wang X, Oberly P, Minnigh MB, Poloyac SM, Carlisle DL, Friedlander RM. Melatonin Inhibits Cytosolic Mitochondrial-DNA Induced Neuroinflammatory Signaling in Accelerated Aging and Neurodegeneration. J Clin Invest. 2020; Mar 17 [Epub ahead of print]. PMID: 321882222.

4. Nigam SK, Bush KT, Bhatnagar V, Poloyac SM, Momper JD. The Systems Biology of Drug Metabolizing Enzymes and Transporters: Relevance to Quantitative Systems Pharmacology. Clin Pharmacol Ther. 2020; Jan 7 [Epub ahead of print]. PMID: 32119114.

5. Zhang J, Bhuiyan MIH, Zhang T, Karimy JK, Wu Z, Fiesler VM, Zhang J, Huang H, Hasan MN, Skrzypiec AE, Mucha M, Duran D, Huang W, Pawlak R, Foley LM, Hitchens TK, Minnigh MB, Poloyac SM, Alper SL, Molyneaux BJ, Trevelyan AJ, Kahle KT, Sun D, Deng X. Modulation of Brain Cation-CL Cotransport via the SPAK Kinase Inhibitor ZT-1a. Nat Commun. 2020; 11(1): 78. PMID: 31911626.

6. Xie Y, Barbosa ACS, Xu M, Oberly PJ, Ren S, Gibbs RB, Poloyac SM, Song W, Fan J, Xie W. Hepatic Estrogen Sulfotransferase Distantly Sensitizes Mice to Hemorrhagic Shock-Induced Acute Lung Injury. Endocrinology. 2020; 161(1). PMID: 31837219.

7. Tang C, Poloyac SM. A Modeling-Based Approach to Estimate Fentanyl Pharmacokinetics in Obese Critically Ill Children. Pediatr Crit Care Med. 2019; 20(12): 1208 - 9. PMID: 31804447.



8. Osier ND, Ziari M, Puccio AM, Poloyac S, Okonkwo DO, Minnigh MB, Beers SR, Conley YP. Elevated Cerebrospinal Fluid Concentrations of N-acetylaspartate Correlate with Poor Outcome in a Pilot Study of Severe Brain Trauma. Brain Inj. 2019; 33(10): 1364-1371. PMID: 31305157.

9. Feng Y, Xie Y, Xu M, Li L, Selcer KW, Oberly PJ, Poloyac SM, Wang H, Li C, Dong F, Yu C, Xie W. Hepatic Steroid Sulfatase Critically Determines Estrogenic Activities of Conjugated Equine Estrogens in Human Cells in vitro and in mice. J Biol Chem. 2019; 294(32): 12112-12121. PMID: 31217279.

10. Abrahamson EE, Poloyac SM, Dixon CE, Dekosky ST, Ikonomovic MD. Acute and Chronic Effects of Single Dose Memantine after Controlled Cortical Impact Injury in Adult Rats. Restor Neurol Neurosci. 2019; 37(3): 245-63. PMID: 31177251.

11. Hagos FT, Horvat CM, Au AK, Conley YP, Li L, Poloyac SM, Kochanek PM, Clark RSB, Empey PE. Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children. Clin Pharmacokinet. 2019; 58(12): 1567-1576. PMID: 31168770.

12. Poloyac SM, Bertz RJ, McDermott L, Marathe P. Pharmacological Optimization for Successful Traumatic Brain Injury Drug Development. J Neurotrauma. 2019 April 10 [Epub ahead of print]. PMID: 30816062.

13. Hagos FT, Adams SM, Poloyac SM, Kochanek PM, Horvat CM, Clark RSB, Empey PE. Membrane Transporters in Traumatic Brain Injury: Pathological, Pharmacotherapeutic, and Developmental Implications. Exp Neurol. 2019; 317: 10-21. PMID: 30797827.

14. Zhang J, Tang C, Oberly PJ, Minnigh MB, Achilles SL, Poloyac SM. A sensitive and robust UPLC-MS/MS method for quantitation of estrogens and progestogens in human serum. Contraception. 2019; 99(4): 244-250. PMID: 30685285.

15. Kochanek PM, Jackson TC, Jha RM, Clark RSB, Okonkwo DO, Bayır H, Poloyac SM, Wagner AK, Empey PE, Conley YP, Bell MJ, Kline AE, Bondi CO, Simon DW, Carlson SW, Puccio AM, Horvat CM, Au AK, Elmer J, Treble-Barna A, Ikonomovic MD, Shutter LA, Taylor DL, Stern AM, Graham SH, Kagan VE, Jackson EK, Wisniewski SR, Dixon CE. Paths to Successful Translation for Severe Traumatic Brain Injury in the Golden Age of Traumatic Brain Injury Research. J Neurotrauma 2019; Feb 1 [Epub ahead of Print]. PMID: 30520681

16. Kochanek PM, Dixon CE, Mondello S, Wang KKK, Lafrenaye A, Bramlett HM, Dietrich WD, Hayes RL, Shear DA, Gilsdorf JS, Catania M, Poloyac SM, Empey PE, Jackson TC, Povlishock JT. Multi-Center Pre-clinical Consortia to Enhance Translation of Therapies and Biomarkers for Traumatic Brain Injury: Operation Brain Trauma Therapy and Beyond. Front Neurol 2018; Aug 7 [Epub Ahead of Print]. PMID: 30131759. PMID: 30131759.

17. Turi ER, Conley Y, Crago E, Sherwood P, Poloyac SM, Ren D, Stanfill AG. Psychosocial Comorbidities Related to Return to Work Rates Following Subarachnoid Hemorrhage. J Occup Rehabil 2018; May 21 [Epub Ahead of Print]. PMID: 29781055.

18. DeWitt DS, Hawkins BE, Dixon CE, Kochanek PM, Armstead W, Bass CR, Bramlett HM, Buki A, Dietrich WD, Ferguson AR, Hall ED, Hayes RL, Hinds SR, LaPlaca MC, Long JB, Meaney DF, Mondello S, Noble-Haeusslein LJ, Poloyac SM, Prough DS, Robertson CS, Saatman KE, Shultz SR, Shear DA, Smith DH, Valadka AB, VandeVord P, Zhang L. Pre-Clinical Testing of Therapies for Traumatic Brain Injury. J Neurotrauma 2018; Aug 30 [Epub Ahead of Print]. PMID: 29756522.

19. Li L, Poloyac SM, Waltkins SC, St Croix CM, Alexander H, Gibson GA, Loughran PA, Kirisci L, Clark RS, Kochanek PM, Vazquez AL, Manole MD. Cerebral microcirculatory alterations and the no-reflow phenomenon in vivo after experimental pediatric cardiac arrest. J Cereb Blood Flow Metab 2019; 39(5): 913 - 925. PMID: 29192562. [Image selected for cover].

20. Hagos FT, Empey PE, Wang P, Ma X, Poloyac SM, Bayir H, Kochanek PM, Bell MJ, Clark RSB. Exploratory Application of Neuropharmacometabolomics in Severe Childhood Traumatic Brain Injury. Crit Care Med 2018; 46(9): 1471-9. PMID: 29742587.

21. Jha RM, Molyneaux BJ, Jackson TC, Wallisch JS, Park SY, Poloyac S, Vagni VA, Janesko-Feldman KL, Hoshitsuki K, Minnigh MB, Kochanek PM. Glibenclamide Produces Region-Dependent Effects on Cerebral Edema in a Combined Injury Model of Traumatic Brain Injury and Hemorrhagic Shock in Mice. J Neurotrauma 2018; 35(17): 2125-35. PMID: 29648981

22. Kochanek PM, Bramlett HM, Dixon CE, Dietrich WD, Mondello S, Wang KKW, Hayes RL, Lafrenaye A, Povlishock JT, Tortella FC, Poloyac SM, Empey P, Shear DA. Operation Brain Trauma Therapy: 2016 Update. Mil Med 2018; 183 (suppl 1): 303-312. PMID: 29635589.

23. Weberding NT, Saladino RA, Minnigh MB, Oberly PJ, Tudorascu DL, Poloyac SM, Manole MD. Adenosine administration with a stopcock technique delivers lower-than-intended drug doses. Ann Emerg Med. 2017 Oct 28 [Epub ahead of print]. PMID: 29089171.

24. Adams SM, Conley YP, Wagner AK, Jha RM, Clark RS, Poloyac SM, Kochanek PM, Empey PE. The pharmacogenomics of severe traumatic brain injury. Pharmacogenomics. 2017; 18(15): 1413-1425. PMID: 28975867.

25. Achilles SL, Mhlanga FG, Musara P, Poloyac SM, Chirenje ZM, Hillier SL. Misreporting of contraceptive hormone use in clinical research participants. Contraception. 2018; 97(4): 346-353. PMID: 28966052; PubMed Central: PMC5858917.

26. Stanfill A, Simpson C, Sherwood P, Poloyac S, Crago E, Kim H, Conley Y. A pilot study on the impact of dopamine, serotonin, and brain-derived neurotrophic factor genotype on long-term functional outcomes after subarachnoid hemorrhage. SAGE Open Med. 2017; Aug 31; 5: 2050312117726725. eCollection. PMID: 28894586.

27. Suofu Y, Li W, Jean-Alphonse FG, Jia J, Khattar NK, Li J, Baranov SV, Leronni D, Mihalik AC, He Y, Cecon E, Wehbi VL, Kim J, Heath BE, Baranova OV, Wang X, Gable MJ, Kretz ES, Di Benedetto G, Lezon TR, Ferrando LM, Larkin TM, Sullivan M, Yablonska S, Wang J, Minnigh MB, Guillaumet G, Suzenet F, Richardson RM, Poloyac SM, Stolz DB, Jockers R, Witt-Enderby PA, Carlisle DL, Vilardaga JP, Friedlander RM. Dual role of mitochondria in producing melatonin and driving GPCR signaling to block cytochrome c release. Proc Natl Acad Sci. 2017; 144(38): E7997 – E8006. PMID: 28874589.

28. Clark RSB, Empey PE, Bayır H, Rosario BL, Poloyac SM, Kochanek PM, Nolin TD, Au AK, Horvat CM, Wisniewski SR, Bell MJ. Phase I randomized clinical trial of N-acetylcysteine in combination with an adjuvant probenecid for treatment of severe traumatic brain injury in children. PLoS One. 2017 Jul 7;12(7): e0180280. PMID: 28686657.

29. Horvat CM, Au AK, Conley YL, Kochanek PM, Li L, Poloyac SM, Empey PE, Clark RS. ABCB1 genotype is associated with fentanyl requirements in critically Ill children. Pediatr Res. 2017 Jul;82(1):29-35. PMID: 28388599.




30. Miller TM, Poloyac SM, Anderson KB, Waddell BL, Messamore E, Yao JK. A rapid UPLC-MS/MS assay for eicosanoids in human plasma: Application to evaluate niacin responsivity. Prostaglandins Leukot Essent Fatty Acids. 2017 Jan 18. [Epub ahead of print]. PMID: 27111064.

31. Jha RM, Puccio AM, Chou SH, Chang CH, Wallisch JS, Molyneaux BJ, Zusman BE, Shutter LA, Poloyac SM, Janesko-Feldman KL, Okonkwo DO, Kochanek PM. Sulfonylurea Receptor-1: A Novel Biomarker for Cerebral Edema in Severe Traumatic Brain Injury. Crit Care Med. 2017 Mar;45(3): e255-e264. PMID: 27845954.

32. Wei Y, Tang C, Sant V, Li S, Poloyac SM, Xie W. A Molecular Aspect in the Regulation of Drug Metabolis: Does PXR-Induced Enzyme Expression Always Lead to Functional Changes in Drug Metabolism? Curr Pharmacol Rep. 2016; 2(4): 187-192. PMID: 27795941.

33. Anderson KB, Poloyac SM, Kochanek PM, Empey PE. Effect of Hypothermia and Targeted Temperature Management on Drug Disposition and Response Following Cardiac Arrest: A Comprehensive Review of Preclinical and Clinical Investigations. Ther Hypothermia Temp Manag. 2016; 6(4): 169-179. PMID: 27622966.

34. Crago EA, Price TJ, Bender CM, Ren D, Poloyac SM, Sherwood PR. Impaired Work Productivity After Aneurysmal Subarachnoid Hemorrhage. J Neurosci Nurs. 2016 Oct;48(5):260-8. PMID: 27579960.

35. Garbacz WG, Lu P, Miller TM, Poloyac SM, Eyre NS, Mayrhofer G, Xu M, Ren S, Xie W. Hepatic Overexpression of CD36 Improves Glycogen Homeostasis and Attenuates High-Fat Diet-Induced Hepatic Steatosis and Insulin Resistance. Mol Cell Biol 2016; 36(21): 2715-27. PMID: 27528620.

36. Hagos FT, Daood MJ, Ocque JA, Nolin TD, Bayir H, Poloyac SM, Kochanek PM, Clark RS, Empey PE. Probenecid, an organic anion transporter 1 and 3 inhibitor, increases plasma and brain exposure of N-acetylcysteine. Xenobiotica. 2017; 47(4): 346-353. PMID: 27278858.

37. Kurz JE, Poloyac SM, Abend NS, Fabio A, Bell MJ, Wainwright MS; for Investigators for the Approaches and Decisions in Acute Pediatric Trial. Variation in Anticonvulsant Selection and Electroencephalographic Monitoring Following Severe Traumatic Brain Injury in Children-Understanding Resource Availability in Sites Participating in a Comparative Effectiveness Study. Pediatr Crit Care Med. 2016; 17(7): 649-57. PMID: 27243415.

38. Li J, Oberly PJ, Poloyac SM, Gibbs RB. A Microsomal Based Method to Detect Aromatase Activity in Different Brain Regions of the Rat using Ultra Performance Liquid Chromatography-Mass Spectrometry. J Steroid Biochem Mol Biol. April, 2016; 163: 113-20. PMID: 27113434.

39. Browning M, Shear DA, Bramlett HM, Dixon CE, Mondello S, Schmid KE, Poloyac SM, Dietrich WD, Hayes RL, Wang KK, Povlishock JT, Tortella FC, Kochanek PM. Levetiracetam Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. J Neurotrauma. 2016; 33(6): 581-94. PMID: 26671550.

40. Kochanek PM, Bramlett HM, Shear DA, Dixon CE, Mondello S, Dietrich WD, Hayes RL, Wang KK, Poloyac SM, Empey P, Povlishock J, Mountney A, Browning M, Deng-Bryant Y, Yan HQ, Jackson TC, Catania M, Glushakova O, Richieri S, Tortella FC. Synthesis of Findings, Current Investigations, and Future Directions: Operation Brain Trauma Therapy. J Neurotrauma. 2016; 33(6): 606-14. PMID: 26671284.

41. Mountney A, Bramlett HM, Dixon CE, Mondello S, Dietrich WD, Wang KK, Caudle K, Empey PE, Poloyac SM, Hayes RL, Povlishock JT, Tortella FC, Kochanek PM, Shear DA. Operation Brain Trauma Therapy: Simvastatin Treatment in Traumatic Brain Injury. J Neurotrauma. 2016; 33(6): 567-80. PMID: 26541177.

2017 Graduate Program Faculty Member of the Year
2015 AACP Academic Leadership Fellow
2015 University of Pittsburgh PLS/Rho Chi Innovations in Teaching Award
2014 University of Pittsburgh Brenneman Scholar Award
2014 University of Pittsburgh Chancellors Distinguished Teaching Award
2013 Fellow of the American College of Critical Care Medicine
2008 Phi Delta Chi Outstanding Chapter Advisor Award
2003 Faculty Member of the Year, Academy of Students of Pharmacy University of Pittsburgh
1996 – 1999 Pre-doctoral Fellow, American Foundation for Pharmaceutical Education
1998 Awarded the S. Elizabeth Helton Award for Graduate Research
1995 Graduated Magna Cum Laude, Doctor of Pharmacy, University of Kentucky
1993 Graduated Magna Cum Laude, Bachelor of Science of Pharmacy, University of Pittsburgh
1993 Upjohn Undergraduate Pharmacy Research Award
1991 Rho Chi Pharmacy Honors Society, Alpha Omicron Chapter

PRESENTATIONS 2016- 2020
AACP Student Affairs Workshop. “Choices, Choices, Choices: Seeking Synergy in PharmD and PhD Admissions.” Chicago, Ill. July 2019

AACP Early Career Faculty Workshop. “Developing a Plan for Career Success”. Chicago, Ill. July 2019

Traumatic Brain Injury Research Symposium on Preclinical Research Symposium, Moody Gardens, Galveston, TX. October 2018.

International and National Neurotrauma Society Meeting. “Drug Discovery and Development to Advance Preclinical and Clinical Translation” Toronto, CA, August 2018.

American Association of Colleges of Pharmacy Annual Meeting. “Suit Up: Power Skills for Successful Research Careers” Boston, MA, July 2018.

American Association of Colleges of Pharmacy Annual Meeting. “Report of the Research and Graduate Affairs Committee” Boston, MA, July 2018.

International Conference on Vasospasm. “Subarachnoid Hemorrhage, the Fatty Acid Metabolite 20-HETE, and Poor Outcomes: A Target for Drug Development?” Huntington Beach, CA, October 2017.

American Association of Colleges of Pharmacy Annual Meeting. “Report of the Research and Graduate Affairs Committee” Nashville, TN, July 2017.

Moody Project Traumatic Brain Injury Research Group Seminar Presentation. “Proper Design of a PK/PD Study to Advance from Preclinical to Clinical Translation.” Galveston, TX, June 14, 2017.

Society of Critical Care Medicine Clinical Pharmacy and Pharmacology Pre-Congress Session. “Learning from Experiences – Tips and Tricks to Start Research Off Right.” Honolulu, HI. January, 2017.

University of Missouri Kansas City Pharmacology Seminar Series. The CYP Fatty Acid Metabolite 20-HETE and Brain Hypoperfusion: A Target for Drug Development?” November, 2016.

The 21st International Symposium on Microsome and Drug Oxidations; Davis, CA. “The CYP Fatty Acid Metabolite 20-HETE and Brain Hypoperfusion: A Target for Drug Development?” October, 2016.

Operation Brain Trauma Therapy (OBTT) Preclinical Testing for TBI Therapy Symposium. Galveston, TX. September, 2016.

The Sun Yat Sen International Graduate Student Symposium. “20-HETE as a biomarker and therapeutic target in brain injury” Guangdong, China, September, 2016.

American Association of Colleges of Pharmacy Annual Meeting. Graduate Education SIG Forum–Trends and Transformations within Graduate Education. “Use of Core Competencies as a Compass to Guide a Unified Future of Graduate Education.” Anaheim, CA, July, 2016.

Winter Eicosanoid Conference. “Session IV: 20-HETE” Baltimore, MD, March, 2016.

AACP Academic Leadership Fellows Program Debate; Tampa, FL. “Change Management is a Reactive Process of Managing Resistance During Change” February, 2016.

ACTIVE - RESEARCH

S10 OD028540-01 (PI: Poloyac)
NIGMS
Period of Support: 01/01/2020 – 01/31/2021
Small Molecule Biomarker Core: TSQ Altis LC-MS/MS

R21/R33 NS107785 (MPI: Poloyac and McDermott)
NINDS: Innovation Grants to Nurture Initial Translational Efforts (IGNITE)
Period of Support: 07/15/2018 – 07/14/2021
20-HETE Formation Inhibitors in Cardiac Arrest

UM1AI068633 (Co-I: Poloyac, S)
Magee-Womens Health Corp.
Period of Support: 12/1/16 - 11/30/20
Laboratory Center (LC): Microbicide Trails Network-Protocol

TL1 (Reis) Role: Poloyac Co-Director of Predoctoral Training
NIH
Period of Support: 07/01/2016 – 6/30/2021
University of Pittsburgh Clinical and Translational Science Institute

R01 HD075750 (PI: Manole; Co-PI: Poloyac)
NICHD
Period of Support: 9/10/13 – 5/31/18 NCE
CYP 450 Mediated CBF Dysregulation and Neurotoxicity in Pediatric Cardiac Arrest

U19 AI068021-11 (Greenberger)
NIH
Period of Support: 9/1/15 - 8/31/20
CORE F: Signature-Directed, Sequential Delivery of Radiation Mitigators

View CV

In some browsers, the CV link may not automatically open. You may right-click on the link to open in a new tab to view the CV file.